|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
11.07.25 - 10:15
|
Rhythm Pharmaceuticals +50%: Kauftipp schlägt ein! (Sharedeals)
|
|
|
Rhythm Pharmaceuticals, unser kürzlicher Kauftipp, ist zwischenzeitlich explodiert. Das Biotech-Unternehmen hat starke Daten zu seinem Adipositas-Medikament Bivamelagon veröffentlicht und frisches Geld eingesammelt. Aktie geht steil nach Daten Ich hatte die Rhythm-Aktie bei einem Kurs von 63,19 US$ erst vergangene Woche vorgestellt und zum Kauf empfohlen. Vorgestern ging es bereits steil nach oben: Positive Studiendaten zu […]
The post Rhythm Pharmaceuticals +50%: Kauftipp schlägt ein! first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
09.07.25 - 22:18
|
Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire EN)
|
|
|
BOSTON, July 09, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) (“Rhythm”), a global, commercial-stage biopharmaceutical company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, today announced a proposed public offering of $150 million of its common stock. All securities in the offering will be offered by Rhythm. In addition, Rhythm intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of common stock at the public offering price, less the underwriting discounts and commissions....
|
|
|
|
|
|
|
08.07.25 - 22:03
|
Rhythm Pharmaceuticals To Announce Topline Results from Phase 2 Trial Evaluating Oral MC4R Agonist Bivamelagon in Acquired Hypothalamic Obesity (GlobeNewswire EN)
|
|
|
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced the Company will hold a conference call and webcast on Wednesday, July 9, 2025 at 8:00 a.m. ET to disclose topline results from the randomized, placebo-controlled portion of the Phase 2 trial evaluating bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
